Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

Software-only products providing free-standing treatment represent a key healthcare opportunity for incumbents.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Social distancing may be necessary for two years or more. Here's where remote care comes into play.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

The recent rise of custom-made drugs is already redefining the state of regulation, society, and the economy.

Researcher, PreScouter

In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.

Partner, Health and Life Sciences, Oliver Wyman
Former Partner, Health & Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

It's time to get comfortable with being uncomfortable.

Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

How to ensure medications work as intended for different patient populations.

Chief Executive Officer, Aetion
Partner, Health and Life Sciences, Oliver Wyman

A series of perspectives on the state of data in healthcare.

Some of our 2018 predictions on consolidation, pharma, and investment came true, while others were less predictable.

Director, Marsh & McLennan Advantage, Healthcare

Once J.P. Morgan Healthcare Week comes to a close, companies will need to show as much as they tell.

Chief Strategist, Health Practice, Edelman

The key to measurement-based digital mental healthcare intervention and assessment? A patient's smartphone.

Insights in your inbox

Subscribe